

09857751

> d his

(FILE 'HOME' ENTERED AT 12:05:36 ON 09 DEC 2002)

FILE 'REGISTRY' ENTERED AT 12:05:43 ON 09 DEC 2002
L1 STRUCTURE uploaded

L2 50 S L1
L3 STRUCTURE uploaded
L4 50 S L3

FILE 'STNGUIDE' ENTERED AT 12:12:01 ON 09 DEC 2002

FILE 'REGISTRY' ENTERED AT 12:15:50 ON 09 DEC 2002
L5 STRUCTURE uploaded
L6 13 S L5
L7 STRUCTURE uploaded
L8 12 S L7
L9 200 S L7 SSS FULL

FILE 'CAPLUS' ENTERED AT 12:18:32 ON 09 DEC 2002

L10 53 S L9
L11 33 S L10 AND PATENT/DT
L12 1 S L11 AND XA
L13 1 S L10 AND ANTITHROMBOTIC

FILE 'STNGUIDE' ENTERED AT 12:21:30 ON 09 DEC 2002

FILE 'REGISTRY' ENTERED AT 12:33:53 ON 09 DEC 2002
L14 STRUCTURE uploaded
L15 1 S L14 SUB=L9 SAMPLE
L16 8 S L14 SSS FULL SUB=L9

FILE 'CAPLUS' ENTERED AT 12:36:19 ON 09 DEC 2002
L17 2 S L16

FILE 'STNGUIDE' ENTERED AT 12:38:46 ON 09 DEC 2002





FILE 'REGISTRY' ENTERED AT 12:42:14 ON 09 DEC 2002
L18 STRUCTURE uploaded
L19 1 S L18 SUB=L9 SAMPLE
L20 STRUCTURE uploaded
L21 50 S L20
L22 1 S L20 SUB=L9 SAMPLE
L23 STRUCTURE uploaded
L24 1 S L23 SAMPLE SUB=L9
L25 25 S L23 FULL SUB=L9

FILE 'CAPLUS' ENTERED AT 12:50:15 ON 09 DEC 2002
L26 7 S L25
L27 5 S L26 NOT L17
 E BEIGHT D/IN
L28 40 S E4-E5

=> s 110 and 128
L29 1 L10 AND L28

=> s 129 not 126
L30 0 L29 NOT L26







=>



chain nodes :
 7 8 37 39 40 44 45
 ring nodes :
 1 2 3 4 5 6 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
 28 29 30 31 32
 chain bonds :
 5-7 6-40 7-8 7-37 9-44 20-45 37-39
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14 15-16 15-20 16-17
 17-18 18-19 19-20 21-22 21-26 22-23 23-24 24-25 25-26 27-28 27-32 28-29 29-30
 30-31 31-32
 exact/norm bonds :
 6-40 7-8 7-37 9-44 20-45 37-39
 exact bonds :
 5-7
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14 15-16 15-20 16-17
 17-18 18-19 19-20 21-22 21-26 22-23 23-24 24-25 25-26 27-28 27-32 28-29 29-30
 30-31 31-32
 isolated ring systems :
 containing 1 : 9 : 15 : 21 : 27 :

 G1:[*1],[*2],[*3],[*4]
 G3:CH3,MeO,Cl,F,S
 G4:C,O,N
 Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:Atom 11:Atom
 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom
 22:Atom

23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom
32:Atom 37:CLASS 39:CLASS 40:CLASS 44:CLASS 45:CLASS



chain nodes :

7 8 37 39 40 43 44 46 47 50 51 52 56 57

ring nodes :

1 2 3 4 5 6 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
28 29 30 31 32

chain bonds :

5-7 6-40 7-8 7-37 9-56 20-57 37-39 43-44 44-46 46-47 50-51 51-52

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14 15-16 15-20 16-17
17-18 18-19 19-20 21-22 21-26 22-23 23-24 24-25 25-26 27-28 27-32 28-29 29-30
30-31 31-32

exact/norm bonds :

6-40 7-8 7-37 9-56 20-57 37-39 43-44 44-46 46-47 50-51 51-52

exact bonds :

5-7

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14 15-16 15-20 16-17
17-18 18-19 19-20 21-22 21-26 22-23 23-24 24-25 25-26 27-28 27-32 28-29 29-30
30-31 31-32

isolated ring systems :

containing 1 : 9 : 15 : 21 : 27 :

G1:[*1], [*2], [*3], [*4]

G3:CH3,MeO,Cl,F,S

G4:C,O,N

G5:[*5], [*6]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom
32:Atom 37:CLASS 39:CLASS 40:CLASS 43:CLASS 44:CLASS 46:CLASS 47:Atom 50:CLASS
51:CLASS 52:Atom 56:CLASS 57:CLASS

Generic attributes :

47:

Number of Carbon Atoms : less than 7

Number of Hetero Atoms : less than 2





Type of Ring System : Monocyclic

52:

Number of Carbon Atoms : less than 7

Number of Hetero Atoms : less than 2

Type of Ring System : Monocyclic



chain nodes :

7 8 23 25 26 29 30 32 33 36 37 38 42 43

ring nodes :

1 2 3 4 5 6 9 10 11 12 13 14 15 16 17 18 19 20

chain bonds :

5-7 6-26 7-8 7-23 9-42 20-43 23-25 29-30 30-32 32-33 36-37 37-38

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14 15-16 15-20 16-17
17-18 18-19 19-20

exact/norm bonds :

6-26 7-8 7-23 9-42 20-43 23-25 29-30 30-32 32-33 36-37 37-38

exact bonds :

5-7

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14 15-16 15-20 16-17
17-18 18-19 19-20

isolated ring systems :

containing 1 : 9 : 15 :

G1:[*1], [*2]

G3:CH3,MeO,Cl,F,S

G4:C,O,N

G5:[*3], [*4]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 23:CLASS
25:CLASS 26:CLASS 29:CLASS 30:CLASS 32:CLASS 33:Atom 36:CLASS 37:CLASS 38:Atom
42:CLASS

43:CLASS

Generic attributes :

33:

Number of Carbon Atoms : less than 7
Number of Hetero Atoms : less than 2
Type of Ring System : Monocyclic

38:


Number of Carbon Atoms : less than 7
Number of Hetero Atoms : less than 2
Type of Ring System : Monocyclic

09857751

=> d 1-2 bib abs hitstr


L17 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2002 ACS
AN 2000:457059 CAPLUS
DN 133:89437
TI Preparation of heteroaryl-substituted aromatic amides as factor Xa
inhibitors
IN Beight, Douglas Wade; Craft, Trelia Joyce; Denny, Carl Penman;
Franciskovich, Jeffry Bernard; Goodson, Theodore, Jr.; Hall, Steven
Edward; Herron, David Kent; Joseph, Sajan Pariyadan; Klimkowski, Valentine
Joseph; Masters, John Joseph; Mendel, David; Milot, Guy; Pineiro-Nunez,
Marta Maria; Sawyer, Jason Scott; Shuman, Robert Theodore; Smith, Gerald
Floyd; Tebbe, Anne Louise; Tinsley, Jennifer Marie; Weir, Leonard Clayton;
Wikel, James Howard; Wiley, Michael Robert; Yee, Ying Kwong
PA Eli Lilly and Co., USA; Kyle, Jeffrey, Alan; et al.
SO PCT Int. Appl., 403 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 2000039118 A1 20000706 WO 1999-US29946 19991215
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
EP 1140903 A1 20011010 EP 1999-964279 19991215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO
JP 2002533454 T2 20021008 JP 2000-591029 19991215
PRAI US 1998-113556P P 19981223
WO 1999-US29946 W 19991215
OS MARPAT 133:89437
GI




AB The title compds. [I; A3-A6, together with the two carbons to which they are attached, complete a substituted benzene in which A3 = CR3, A4 = CR4, A5 = CR5, and A6 = CR6 (wherein R3 = H, Me, MeO, etc.; one of R4 and R5 = H, alkyl, halo, etc.; the other of R4 and R5 = H; R6 = H, Me, F, etc.); L1 = CONH; Q1 = 2-pyridinyl (un)substituted at the 5-position, 3-pyridinyl (un)substituted at the 6-position, 2-pyrimidinyl (un)substituted at the 5-position, etc.; R2 = L2Q2 (L2 = NHCO, NHCH2, OCH2, etc.; Q2 = (un)substituted piperidinyl, piperazinyl, Ph, etc.)] and their pharmaceutically acceptable salts, useful as inhibitors of factor Xa (no data), were prep'd. and formulated. E.g., a multi-step synthesis of II.HCl was given. In general, compds. I are effective at 0.01-1000 mg/kg/day.
IT 280768-70-9P 280768-71-0P 280771-11-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (prepn. of heteroaryl-substituted arom. amides as factor Xa inhibitors)
RN 280768-70-9 CAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(5-chloro-2-pyrimidinyl)amino]carbonyl]phenyl]-1-(4-pyridinyl)- (9CI) (CA INDEX NAME)


09857751



RN 280768-71-0 CAPLUS
CN 4-Piperidinecarboxamide, N-[2-[(6-chloro-3-pyridazinyl)amino]carbonyl]phenyl]-1-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 280771-11-1 CAPLUS
CN 4-Piperidinecarboxamide, N-[4-chloro-2-[(6-chloro-3-pyridazinyl)amino]carbonyl]phenyl]-1-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


IT 280773-28-6P 280773-30-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of heteroaryl-substituted arom. amides as factor Xa inhibitors)
RN 280773-28-6 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[4-chloro-2-[(6-chloro-3-pyridazinyl)amino]carbonyl]phenyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 280773-30-0 CAPLUS
CN 4-Piperidinecarboxamide, N-[4-chloro-2-[(6-chloro-3-pyridazinyl)amino]carbonyl]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


09857751

CRN 280773-29-7
CMF C17 H17 C12 N5 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2002 ACS
 AN 2000:335387 CAPLUS
 DN 132:334364
 TI Preparation of anthranilic acid amides as vascular endothelial growth factor receptor inhibitors.
 IN Huth, Andreas; Seidelmann, Dieter; Thierauch, Karl-Heinz; Bold, Guido; Manley, Paul William; Furet, Pascal; Wood, Jeanette Marjorie; Mestan, Jurgen; Bruggen, Jose; Ferrari, Stefano; Kruger, Martin; Ottow, Eckhard; Menrad, Andreas; Schirner, Michael
 PA Schering Aktiengesellschaft, Germany; Novartis Aktiengesellschaft
 SO PCT Int. Appl., 96 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000027819	A2	20000518	WO 1999-EP8478	19991109
	WO 2000027819	A3	20000817		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	DE 19910396	A1	20000907	DE 1999-19910396	19990303
	DE 19910396	C2	20011213		
	BR 9915553	A	20010814	BR 1999-15553	19991109
	EP 1129074	A2	20010905	EP 1999-953967	19991109
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002529452	T2	20020910	JP 2000-580999	19991109
	NO 2001002245	A	20010710	NO 2001-2245	20010507
PRAI	GB 1998-24579	A	19981110		
	DE 1999-19910396	A	19990303		
	WO 1999-EP8478	W	19991109		
OS	MARPAT	132:334364			
GT					



I


AB Title compds. [I; A = NR₂; W = O, S, H₂, NR₈; Z = NR₁₀, N, NR₁₀(CH₂)_q, alkyl, etc.; q = 1-6; AZR₁ = tetrahydroisoquinolinyl, indazolyl, 5-chloroindolyl, etc.; R₁ = (substituted) aryl, heteroaryl; R₂ = H, alkyl; R₃ = (substituted) mono- or bicyclic aryl, heteroaryl; R₄-R₇ = H, halo, (substituted) alkoxy, alkyl, carboxyalkyl; R₅R₆ = dioxetanyl; R₈, R₁₀ = H, alkyl]. Thus, Me N-(4-pyridylmethyl)anthranilate (prepn. given) was stirred with Ph(CH₂)₃NH₂ and Me₃Al were stirred in PhMe to give N-(3-phenylprop-1-yl)-N₂-(4-pyridylmethyl)anthranilamide. The latter inhibited VEGFR I with IC₅₀ = 0.05 .μ.M.

IT 267891-24-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of anthranilic acid amides as VEGF receptor inhibitors)

RN 267891-24-7 CAPLUS


CN Benzamide, N-(5-chloro-2-pyrimidinyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



09857751

=> d 1-5 bib abs hitstr


L27 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2002 ACS
AN 2001:811405 CAPLUS
DN 136:144665
TI Substituted amides and hydrazides of dicarboxylic acids. Part 9. Pharmacological activity of the products of interaction of 2-aminopyridines and 2-aminopyrimidine with dicarboxylic acid anhydrides
AU Kolotova, N. V.; Koz'minykh, V. O.; Dolzhenko, A. V.; Koz'minykh, E. N.; Kotegov, V. P.; Godina, A. T.; Syropyatov, B. Ya.; Novoselova, G. N.
CS State Pharmaceutical Academy, Perm, Russia
SO Pharmaceutical Chemistry Journal (Translation of Khimiko-Farmatsevicheskii Zhurnal) (2001), 35(3), 146-150
CODEN: PCJOAU; ISSN: 0091-150X
PB Kluwer Academic/Consultants Bureau
DT Journal
LA English
AB The interaction of 2-aminopyridine, 2-amino-5-bromopyridine, and 2-amino-4-picoline with citraconic anhydride was studied. The reaction proceeded in Et acetate at room temp. and was accompanied by instantaneous crystn. of the products. The 1H NMR spectra of the reaction products contained a clear signal due to diastereotopic geminal protons of the 3-CH₂ methylene group, representing two doublets of the AB-system in the regions of 2.89-2.97 and 3.21-3.27 ppm. This indicated the formation of 4-methyl-2-oxo-3,4-dihydropyridol[1,2-a]pyrimidine-4-carboxylic acids rather than pyridylamides of citraconic acid. The presence of the characteristic signal due to the 3-CH₂ group allowed the rejection of the possible isomer structure of 3-methyl-2-oxo-3,4-dihydropyridol[1,2-a]pyrimidine-4-carboxylic acids.
IT 393802-70-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(pharmacol. activity of products of interaction of 2-aminopyridines and 2-aminopyrimidine with dicarboxylic acid anhydrides)
RN 393802-70-5 CAPLUS
CN Benzoic acid, 3-nitro-2-[(2-pyrimidinylamino)carbonyl]- (9CI) (CA INDEX NAME)



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L27 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2002 ACS
AN 1999:768118 CAPLUS
DN 132:92965
TI Electron ionization mass spectrometric studies of 1,2-dihydro-2-[2'-pyridyl, 4'-pyridyl and 2',6'-pyrimidyl]-3H-indazol-3-ones
AU Raza, Abdul R.; Rama, Nasim H.; Rehman, I.
CS Department of Chemistry, Quaid-i-Azam University, Islamabad, 45320, Pak.
SO Journal of the Chemical Society of Pakistan (1999), 21(1), 65-68
CODEN: JCSPDF; ISSN: 0253-5106
PB Chemical Society of Pakistan
DT Journal
LA English
AB Electron-ionization mass spectra (EIMS) of 1,2-dihydro-2-(2-pyridyl-, 4-pyridyl and -2,6-pyrimidyl)-3H-indazol-3-ones and their related 2-nitrobenzamides are described. The mol. formulas are further confirmed by high-resoln. EIMS matching of mol.-ion peaks.
IT 175653-49-3, Benzamide, 2-nitro-N-2-pyrimidinyl-
RL: PEP (Physical, engineering or chemical process); RCT (Reactant); PROC (Process); RACT (Reactant or reagent)
(electron-ionization mass spectrometric studies of dihydropyridyl- and -pyrimidylindazolones and related nitrobenzamides)
RN 175653-49-3 CAPLUS
CN Benzamide, 2-nitro-N-2-pyrimidinyl- (9CI) (CA INDEX NAME)

09857751




RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L27 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2002 ACS
AN 1996:120235 CAPLUS
DN 124:289334
TI Synthetic approaches towards some new 1,2-dihydro-2-(heterocycl1)-3H-indazol-3-ones
AU Saeed, Aamer; Rama, Nasim H.
CS Dep. of Chemistry, Quaid-i-Azam Univ., Islamabad, Pak.
SO Journal of the Chemical Society of Pakistan (1995), 17(4), 232-6
CODEN: JCSPDF; ISSN: 0253-5106
PB Chemical Society of Pakistan
DT Journal
LA English
AB Two different synthetic approaches viz. reductive cyclization of N-heterocycl1-2-nitrobenzanilides and the base catalyzed cyclization of 2-azido-N-heterocycl1benzanilides were applied to the synthesis of some new 2-heterocycl1indazol-3-ones (4). However, both methods exhibited limited success, and, based upon the results of these investigations, a safe strategy involving the heteroarylation at N-2 of 1-carboethoxyindazolone, followed by deprotection at N-1 to furnish 4 was suggested for prepn. of 2-heterocycl1indazolones.
IT 175653-49-3P 175653-50-6P 175653-61-9P
175653-62-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and attempted cyclization of)
RN 175653-49-3 CAPLUS
CN Benzamide, 2-nitro-N-2-pyrimidinyl- (9CI) (CA INDEX NAME)



RN 175653-50-6 CAPLUS
CN Benzamide, N-(4,6-dimethyl-2-pyrimidinyl)-2-nitro- (9CI) (CA INDEX NAME)




RN 175653-61-9 CAPLUS
CN Benzamide, 2-azido-N-2-pyrimidinyl- (9CI) (CA INDEX NAME)



RN 175653-62-0 CAPLUS
CN Benzamide, 2-azido-N-(4,6-dimethyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)

09857751



L27 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2002 ACS

AN 1989:423509 CAPLUS

DN 111:23509

TI Substituted 3-(4-nitrophenoxy)pyrazoles, their herbicidal use and compositions, and processes and intermediates for their preparation

IN Moedritzer, Kurt; Lee, Len Fang; Rogers, Michael David; Anderson, Dennis Keith; Singh, Rajendra Kumar; Gaede, Bruce John; Torrence, Lisa Louise

PA Monsanto Co., USA

SO Eur. Pat. Appl., 338 pp.

CODEN: EPXXDW

DT Patent


LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 295233	A2	19881214	EP 1988-870104	19880607
	EP 295233	A3	19890315		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	US 4855442	A	19890808	US 1988-175461	19880413
	US 4948902	A	19900814	US 1988-175462	19880413
	AU 8817450	A1	19881208	AU 1988-17450	19880607
	AU 607225	B2	19910228		
	FI 8802680	A	19881209	FI 1988-2680	19880607
	DK 8803086	A	19881209	DK 1988-3086	19880607
	NO 8802509	A	19881209	NO 1988-2509	19880607
	NO 169387	B	19920309		
	NO 169387	C	19920617		
	BR 8802760	A	19881227	BR 1988-2760	19880607
	JP 01025764	A2	19890127	JP 1988-140361	19880607
	JP 05075746	B4	19931021		
	CN 1033457	A	19890621	CN 1988-103374	19880607
	CN 1021191	B	19930616		
	ZA 8804050	A	19900228	ZA 1988-4050	19880607
	HU 52063	A2	19900628	HU 1988-2946	19880607
	HU 204259	B	19911230		
	DD 289461	A5	19910502	DD 1988-316491	19880607
	PL 156730	B1	19920430	PL 1988-279592	19880607
	PL 156831	B1	19920430	PL 1988-279591	19880607
	PL 157154	B1	19920529	PL 1988-272883	19880607
	NO 8900595	A	19881209	NO 1989-595	19890210
	NO 170276	B	19920622		
	NO 170276	C	19920930		
	NO 8900596	A	19881209	NO 1989-596	19890210
	US 4964895	A	19901023	US 1990-471686	19900130
PRAI	US 1987-59431		19870608		
	US 1987-59712		19870608		
	US 1988-175460		19880413		
	US 1988-175461		19880413		
	US 1988-175462		19880413		
	US 1988-175463		19880413		
	NO 1988-2509		19880607		

OS CASREACT 111:23509; MARPAT 111:23509

GI



I



II

AB Title compds. I [R1 = Me, Et, halomethyl, haloethyl; R2 = Cl, cyano, halomethyl, haloethyl, MeS, EtS, MeS(O), EtS(O), MeS(O)2, EtS(O)2, MeOCH2; R3 = H, halo, NO2; Z = H, substituent of mol. wt. < 300] are prep'd.

09857751


as herbicides. 3-Fluoroacetophenone underwent nitration by fuming HNO₃ in the 6-position, followed by condensation with 5-trifluoromethyl-4-chloro-3-hydroxy-1-methylpyrazole to give (trifluoromethyl)chloro(nitrophenoxy)methylpyrazole II (Z = Ac). This underwent oximation by NH₂OH.HCl, followed by etherification of the oxime with BrCH₂CO₂Me, to give II (Z = MeOCOCH₂ON:CMe) (III). At 11.21 kg/ha postemergence, III gave 100% control of 9/10 tested weeds, including barnyardgrass, velvetleaf, and Pennsylvania smartweed.

IT 121299-66-9P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of, as herbicide)

RN 121299-66-9 CAPLUS

CN Benzamide, 5-[(4-chloro-1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)oxy]-N-(4,6-dimethyl-2-pyrimidinyl)-2-nitro- (9CI) (CA INDEX NAME)



L27 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2002 ACS

AN 1979:121516 CAPLUS

DN 90:121516

TI Condensation of acanthranil and phenylanthranil with certain aminoheterocycles. Attempted preparation of some 2,3-disubstituted 4(3H)-quinazolinones

AU El-Zanfally, S.

CS Fac. Pharm., Cairo Univ., Cairo, Egypt


SO Egyptian Journal of Pharmaceutical Sciences (1978), Volume Date 1976, 17(1), 29-34

CODEN: EJPSBZ; ISSN: 0301-5068

DT Journal

LA English

GI




AB Treating 2-methyl-4H-3,1-benzoxazin-4-ones (I; X = O; R = Me; R1 = H, Br) with amines R₂NH₂ (R₂ = 2-pyridyl, 4-antipyrinyl) yielded 35-81% the corresponding quinazolinones (I; X = NR₂). The reactions were carried out by fusing the reactants at 150-60.degree. for 3 h or by refluxing in pyridine-dioxane for 2 h. Similar reaction of I (X = O, R = Ph, R1 = H) with R₂NH₂ (R₂ = 2-, 3-, or 4-pyridyl; 2-pyrimidinyl, or 4-antipyrinyl) gave o-R₂NHCOC₆H₄NHCOPh.

IT 69589-68-0P

RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)

RN 69589-68-0 CAPLUS


CN Benzamide, 2-(benzoylamino)-N-2-pyrimidinyl- (9CI) (CA INDEX NAME)



09857751

L35 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2002 ACS
AN 2002:408645 CAPLUS
DN 137:6352
TI Preparation of benzanilide derivatives as inhibitors of activated blood coagulation factor X
IN Ishihara, Tsukasa; Hirayama, Fukushi; Sugawara, Keizo; Koga, Yuji; Kadokura, Takeshi; Shigenaga, Takeshi
PA Yamanouchi Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002042270	A1	20020530	WO 2001-JP10176	20011121
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2002024064	A5	20020603	AU 2002-24064	20011121
PRAI	JP 2000-356146	A	20001122		
	JP 2000-390321	A	20001222		
	WO 2001-JP10176	W	20011121		
OS	MARPAT	137:6352			
GI					





I

AB The title compds. I [X₁ = CONR₅, etc.; X₂ = CONR₆, etc.; R₁ = halo, etc.; R₂, R₃ = H, halo, CN, etc.; R₄ = H, SO₃H, etc.; ring A = benzene ring, etc.; ring B = piperidine ring (with substituent on N), etc.; further details on ring B are given; R₅, R₆ = H, alkyl] are prep'd. For example, 2'-(2-acetamido-2-deoxy-.beta.-D-glucopyranosyloxy)-4'-bromo-6'-(5-chloro-2-pyridyl)carbamoyl]-1-isopropylpiperidine-4-carboxanilide was prep'd. and its activity against the activated blood coagulation factor X was demonstrated.

IT 432029-24-8P 432029-41-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prep'n. of benzanilide derivs. as inhibitors of activated blood coagulation factor X)



RN 432029-24-8 CAPLUS
CN Benzamide, 3-hydroxy-2-[[[1-(1-methylethyl)-4-piperidinyl]methyl]amino]-N-(5-methyl-2-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

09857751



● HCl

RN 432029-41-9 CAPLUS
CN 4-Piperidinecarboxamide, N-[4-bromo-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-hydroxyphenyl]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2002 ACS
AN 2002:107335 CAPLUS
DN 136:151189
TI Preparation of pyrazinyl-, pyridazinyl-, pyrimidinyl-, and pyridinyl-hexahydrodiazepines and their use as factor Xa inhibitors
IN Herron, David Kent; Joseph, Sajan; Marquart, Angela Lynn; Masters, John Joseph; Mendel, David; Smith, Gerald Floyd; Waid, Philip Parker; Wiley, Michael Robert; Yee, Ying Kwong
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 159 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE


PI WO 2002010154 A2 20020207 WO 2001-US16528 20010718
WO 2002010154 A3 20020627

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2000-221092P P 20000727

OS MARPAT 136:151189

GI




AB Substituted hexahydrodiazepines I [R = H, alkyl, acyl, acetoxy, acetyl, aminoacetyl, alkylamido, etc.; one or two of X, W, Y, and Z equals N and each of the others of X, W, Y and Z is CH; when L = CO or CH₂, Q₁ = (un)substituted pyridinyl- or phenyl-amidophenylamine, in addn. when L = CO, Q₁ may equal Q₂X₂SO₂N(CH₂CH₂)₂N- wherein Q₂ = (un)substituted Ph, benzo[b]thiophen-2-yl or naphthalen-2-yl (X₂ = direct bond, CH₂, ethylene, or ethen-1,2-diyl)], and their pharmaceutically acceptable salts are prepd. and disclosed as factor Xa inhibitors. Thus, II was prepd. by amidation of 2-amino-5-fluoro-N-(5-chloropyridin-2-yl)benzamide with 5-hydroxy-pyrazine-2-carboxylic acid (via its acid chloride) followed by substitution with 1-BOC-hexahydro-1,4-diazepine and subsequent deprotection of the diazepinyl nitrogen. As factor Xa inhibitors, the compds. of the invention are claimed to be useful in the treatment of thromboembolic disorders (no data).

IT 395684-11-4P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of pyrazinyl-, pyridazinyl-, pyrimidinyl-, and pyridinyl-hexahydrodiazepines as factor Xa inhibitors)

RN 395684-11-4 CAPLUS
CN 2-Pyridinecarboxamide, N-[2-[(5-chloro-2-pyridinyl)amino]carbonyl]-4-fluorophenyl-5-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)- (9CI) (CA INDEX NAME)



L35 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2002 ACS
AN 2000:769086 CAPLUS

DN 133:335159

TI Preparation

IN analogs as anticoagulants
Arnaiz, Damian O.; Chou, Yuo-ling; Griedel, Brian D.; Karanjawala,

E.; Kochanny, Monica J.; Lee, Wheeseong; Liang, Amy Mei; Morrissey, Michael M.; Phillips, Gary B.; Sacchi, Karna Lyn; Sakata, Steven T.; Shaw, Kenneth J.; Snider, R. Michael; Wu, Shung C.; Ye, Bin; Zhao, Zuchun

PA Berlex Laboratories, Inc., USA
CO U.S. 113-115 Grant Avenue

SO U.S., 113 pp., Cont.-in-part of U.S. Ser. No. 994,284, abandoned.

CODEN: USXXAM

Patent
English


LA English
FAN CNT ?

APPENDIX 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6140351	A	20001031	US 1998-187459	19981105
CA 2315070	AA	19990701	CA 1998-2315070	19981127

09857751

WO 9932477	A1	19990701	WO 1998-EP7650	19981127
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9918759	A1	19990712	AU 1999-18759	19981127
AU 751856	B2	20020829		
EP 1040108	A1	20001004	EP 1998-963519	19981127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001526283	T2	20011218	JP 2000-525414	19981127
ZA 9811599	A	19990817	ZA 1998-11599	19981217
NO 2000003111	A	20000818	NO 2000-3111	20000616
US 6380221	B1	20020430	US 2000-631450	20000803
PRAI US 1997-994284	B2	19971219		
US 1998-187459	A	19981105		
WO 1998-EP7650	W	19981127		
OS MARPAT 133:335159				
GI				




AB REZDR3 [I; D, E = Z1NR5C(:X), Z1NR5SOO-2, etc.; R, R3 = (un)substituted heterocyclyl or -aryl; R5 = H, (ar)alkyl, aryl; X = O, S, H2; Z = (un)substituted heterocyclylene or -arylene; Z1 = bond, alkylene, alkylidene, etc.] were prepd. as factor Xa, thrombin, and prothrombinase inhibitors. Thus, H2NZCONHC6H4Cl-4 (Z = 4-chloro-1,2-phenylene) (prepn. given) was N-acylated by 3-chloro-4-chloromethyl-2-thiophenecarbonyl chloride and the product aminated by 1-methylpiperazine to give title compd. II. Data for biol. activity of I were given.

IT 229335-90-4P 229336-11-2P 229336-27-0P
229336-52-1P 229336-53-2P 229336-65-6P
229336-95-2P 229337-09-1P 229337-12-6P
229337-14-8P 229337-54-6P 229337-66-0P
229337-74-0P 229338-02-7P 229340-58-3P
229340-88-9P 229341-14-4P 229341-37-1P
229341-88-2P 229342-40-9P 229342-41-0P
229342-43-2P 304021-99-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-pyridinyl-2-[(thienylcarbonyl)amino]benzamides and analogs as anticoagulants)

RN 229335-90-4 CAPLUS


CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[[5-chloro-2-pyridinyl]amino]carbonyl]-6-methoxyphenyl]-4-[[[4,5-dihydro-5-methyl-2-oxazolyl)methylamino]methyl]- (9CI) (CA INDEX NAME)



RN 229336-11-2 CAPLUS
CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[[5-chloro-2-


09857751

pyridinyl)amino]carbonyl]-6-methoxyphenyl]-4-[(methyl[[3-[(methylthio)methyl]-1,2,4-oxadiazol-5-yl)methyl]amino)methyl]- (9CI) (CA INDEX NAME)




RN 229336-27-0 CAPLUS

CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-4-[(4-ethyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)



RN 229336-52-1 CAPLUS

CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-4-[(2-(ethylimino)-5,5-dimethyl-3-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 229336-53-2 CAPLUS

CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-4-[(5S)-2-imino-5-methyl-3-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

09857751




RN 229336-65-6 CAPLUS

CN 2-Thiophenecarboxamide, 4-[(2-amino-4,5-dihydro-4-oxo-1H-imidazol-1-yl)methyl]-3-chloro-N-[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 229336-95-2 CAPLUS


CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-4-[(2-(1-methylethyl)-1H-imidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 229337-09-1 CAPLUS


CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-4-[(4,5-dihydro-1H-imidazol-2-ylthio)methyl]- (9CI) (CA INDEX NAME)

09857751




RN 229337-12-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-4-(4,5-dihydro-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 229337-14-8 CAPLUS


CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-4-[(1-iminoethyl)methylamino]methyl- (9CI) (CA INDEX NAME)



RN 229337-54-6 CAPLUS


CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-(4-morpholinyl)phenyl]-4-[(4,5-dihydro-2-oxazolyl)ethylamino]methyl- (9CI) (CA INDEX NAME)

09857751




RN 229337-66-0 CAPLUS

CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[[[5-chloro-2-pyridinyl)amino]carbonyl]-6-[2-(2-methoxyethoxy)ethoxy]phenyl]-4-[[[4,5-dihydro-2-oxazolyl)methylamino]methyl]- (9CI) (CA INDEX NAME)



RN 229337-74-0 CAPLUS

CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[[[5-chloro-2-pyridinyl)amino]carbonyl]-6-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4-[[[methyl(methylsulfonyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 229338-02-7 CAPLUS


CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[[[5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-4-[[[2,6-diamino-7H-purin-7-yl)amino]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 229338-01-6


CMF C24 H19 Cl3 N10 O3 S

09857751



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 229340-58-3 CAPLUS
CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-4-[(5-(hydroxymethyl)-1-methyl-1H-imidazol-2-yl)thio]methyl-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 229337-10-4
CMF C24 H20 Cl13 N5 O4 S2




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 229340-88-9 CAPLUS
CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-4-[(cyanomethyl)methylamino]methyl- (9CI) (CA INDEX NAME)

09857751




RN 229341-14-4 CAPLUS

CN 2-Thiophenecarboxamide, 4-[(6-amino-7H-purin-7-yl)methyl]-3-chloro-N-[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 229336-87-2


CMF C24 H17 Cl13 N8 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 229341-37-1 CAPLUS

CN 2-Thiophenecarboxamide, 4-[(aminocarbonyl)methylamino]methyl]-3-chloro-N-[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 229335-56-2

CMF C21 H18 Cl13 N5 O4 S




CM 2

CRN 76-05-1

09857751

CMF C2 H F3 O2




RN 229341-88-2 CAPLUS

CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4-[(methyl(methylsulfonyl)amino)methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 229337-74-0


CMF C26 H28 Cl3 N5 O5 S2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 229342-40-9 CAPLUS


CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-4-[(2-(cyanomethyl)-4,5-dihydro-1H-imidazol-1-yl)methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 229336-48-5


CMF C24 H19 Cl3 N6 O3 S

09857751



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 229342-41-0 CAPLUS
CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-4-[[4,5-dihydro-2-[(2-hydroxyethyl)amino]-1H-imidazol-1-yl]methyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 229336-72-5
CMF C24 H23 C13 N6 O4 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



09857751


RN 229342-43-2 CAPLUS

CN 2-Thiophenecarboxamide, 3-chloro-N-[(4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl)-4-[(2-(hydroxymethyl)-1H-imidazol-1-yl)methyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 229336-41-8


CMF C23 H18 Cl3 N5 O4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 304021-99-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-chloro-N-[(4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl)-4-[(4-methyl-1H-imidazol-1-yl)methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 229336-29-2


CMF C23 H18 Cl3 N5 O3 S



CM 2

09857751

CRN 76-05-1
CMF C2 H F3 O2




IT 304022-43-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of N-pyridinyl-2-[(thienylcarbonyl)amino]benzamides and analogs as anticoagulants)

RN 304022-43-3 CAPLUS

CN Benzoic acid, 2-hydroxy-, compd. with 3-chloro-N-[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-4-[(methyl-2-oxazolylamino)methyl]-2-thiophenecarboxamide (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 229335-87-9
CMF C23 H18 C13 N5 O4 S



CM 2

CRN 69-72-7
CMF C7 H6 O3



RE.CNT 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2002 ACS
AN 2000:457059 CAPLUS

DN 133:89437

TI Preparation of heteroaryl-substituted aromatic amides as factor Xa inhibitors

IN Beight, Douglas Wade; Craft, Trelia Joyce; Denny, Carl Penman; Franciskovich, Jeffry Bernard; Goodson, Theodore, Jr.; Hall, Steven Edward; Herron, David Kent; Joseph, Sajan Pariyadan; Klimkowska, Valentine Joseph; Masters, John Joseph; Mendel, David; Milot, Guy; Pineiro-Nunez, Marta Maria; Sawyer, Jason Scott; Shuman, Robert Theodore; Smith, Gerald Floyd; Tebbe, Anne Louise; Tinsley, Jennifer Marie; Weir, Leonard Crayton; Wikel, James Howard; Wiley, Michael Robert; Yee, Ying Kwong
PA Eli Lilly and Co., USA; Kyle, Jeffrey, Alan; et al.

SO PCT Int. Appl., 403 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
PI WO 2000039118	A1	20000706	WO 1999-US29946	19991215
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,				

THIS APP

09857751

IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1140903 A1 20011010 EP 1999-964279 19991215

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO


JP 2002533454 T2 20021008 JP 2000-591029 19991215

PRAI US 1998-113556P P 19981223

WO 1999-US29946 W 19991215

OS MARPAT 133:89437

GI





AB The title compds. [I; A3-A6, together with the two carbons to which they are attached, complete a substituted benzene in which A3 = CR3, A4 = CR4, A5 = CR5, and A6 = CR6 (wherein R3 = H, Me, MeO, etc.; one of R4 and R5 = H, alkyl, halo, etc.; the other of R4 and R5 = H; R6 = H, Me, F, etc.); L1 = CONH; Q1 = 2-pyridinyl (un)substituted at the 5-position, 3-pyridinyl (un)substituted at the 6-position, 2-pyrimidinyl (un)substituted at the 5-position, etc.; R2 = L2Q2 (L2 = NHCO, NHCH2, OCH2, etc.; Q2 = (un)substituted piperidinyl, piperazinyl, Ph, etc.)] and their pharmaceutically acceptable salts, useful as inhibitors of factor Xa (no data), were prep'd. and formulated. E.g., a multi-step synthesis of II.HCl was given. In general, compds. I are effective at 0.01-1000 mg/kg/day.

IT 280769-11-1P 280770-93-6P 280771-49-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of heteroaryl-substituted arom. amides as factor Xa inhibitors)



RN 280769-11-1 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[(4-piperidinylmethyl)amino]- (9CI) (CA INDEX NAME)





RN 280770-93-6 CAPLUS

CN Benzamide, 5-chloro-N-(5-fluoro-2-pyridinyl)-2-[(4-piperidinylmethyl)amino]- (9CI) (CA INDEX NAME)




09857751



RN 280771-49-5 CAPLUS

CN Benzoic acid, 3-[(5-chloro-2-pyridinyl)amino]carbonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]methyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



IT 280768-73-2P 280769-17-7P 280769-27-9P

280769-50-8P 280769-70-2P 280769-89-3P

280769-95-1P 280770-08-3P 280770-34-5P


280770-82-3P 280771-00-8P 280771-35-9P

280771-39-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of heteroaryl-substituted arom. amides as factor Xa inhibitors)


RN 280768-73-2 CAPLUS

CN 4-Piperidinecarboxamide, N-[2-[(5-chloro-2-pyridinyl)amino]carbonyl]phenyl-1-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 280769-17-7 CAPLUS

CN 4-Piperidinecarboxamide, N-[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]phenyl-1-(1-ethylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)





● HCl

RN 280769-27-9 CAPLUS


09857751

CN Benzamide, 5-chloro-N-(5-chloro-2-pyridinyl)-2-[[1-(1-methylethyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)





RN 280769-50-8 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[1-(4-pyridinylmethyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 280769-70-2 CAPLUS


CN Benzamide, 5-chloro-2-[[1-(1-methylethyl)-4-piperidinyl]methyl]amino]-N-(5-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 280769-89-3 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[1-(3-thienylmethyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)


09857751




RN 280769-95-1 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-[(3-hydroxyphenyl)methyl]-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 280770-08-3 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-(3-furanyl methyl)-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 280770-34-5 CAPLUS
CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[1-[1-(3-fluorophenyl)ethyl]-4-piperidinyl]methyl]amino]- (9CI) (CA INDEX NAME)



09857751



RN 280770-82-3 CAPLUS

CN Benzamide, N-(5-chloro-2-pyridinyl)-2-[[[(1-cyclohexyl-4-piperidinyl)methyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 280771-00-8 CAPLUS


CN 1-Piperidinepropanamide, 4-[[[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]phenyl]amino]methyl- (9CI) (CA INDEX NAME)



RN 280771-35-9 CAPLUS


CN 4-Piperidinecarboxamide, N-[2-[(5-chloro-2-pyridinyl)amino]carbonyl]-4-[(1E)-2-cyanoethenyl]phenyl]-1-(1-methylethyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 280771-39-3 CAPLUS

CN 4-Piperidinecarboxamide, N-[2-[(5-chloro-2-pyridinyl)amino]carbonyl]-4-(hydroxymethyl)phenyl]-1-(1-methylethyl)- (9CI) (CA INDEX NAME)



IT 280771-90-6P 280773-87-7P

09857751

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of heteroaryl-substituted arom. amides as factor Xa inhibitors)


RN 280771-90-6 CAPLUS

CN 4-Piperidinecarboxamide, N-[2-[(5-chloro-2-pyridinyl)amino]carbonyl]-4-fluorophenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 280771-89-3


CMF C18 H18 Cl F N4 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 280773-87-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[2-[(5-chloro-2-pyridinyl)amino]carbonyl]-4-(methylthio)phenyl]amino]carbonyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2002 ACS
AN 1999:421679 CAPLUS

DN 131:87925

TI Preparation of heteroarylcarbonylaminobenzamides and related compounds as anticoagulants.

IN Arnaiz, Damian O.; Chou, Yuo-Ling; Karanjawala, Rushad E.; Kochanny, Monica J.; Lee, Wheeseong; Liang, Amy Mei; Morrissey, Michael M.; Phillips, Gary B.; Sacchi, Karna Lyn; Sakata, Stephen T.; Shaw, Kenneth J.; Snider, R. Michael; Wu, Shung C.; Ye, Bin; Zhao, Zuchun; Griedel, Brian D.

PA Schering Aktiengesellschaft, Germany

SO PCT Int. Appl., 326 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
PI WO 9932477	A1	19990701	WO 1998-EP7650	19981127
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,				

DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG,
 KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
 NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
 UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
 CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 US 6140351 A 20001031 US 1998-187459 19981105
 CA 2315070 AA 19990701 CA 1998-2315070 19981127
 AU 9918759 A1 19990712 AU 1999-18759 19981127
 AU 751856 B2 20020829
 EP 1040108 A1 20001004 EP 1998-963519 19981127
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI
 JP 2001526283 T2 20011218 JP 2000-525414 19981127
 NO 2000003111 A 20000818 NO 2000-3111 20000616
 PRAI US 1997-994284 A 19971219
 US 1998-187459 A 19981105
 WO 1998-EP7650 W 19981127
 OS MARPAT 131:87925
 GI




AB Title compds. [I; $m = 1-3$; $n = 1-5$; B, Q = atoms to form aryl, heterocyclyl rings; D, E = NR₅CX; R₈NR₅CX, NR₅SO_p, etc.; p = 0-2; X = O, S, H₂; R₁ = H, alkyl, aryl, aralkyl, halo, haloalkyl, cyano, OR₅, CO₂R₅, NR₅R₆, CONR₅R₆ (substituted) heterocyclyl, etc.; R₂ = H, alkyl, aryl, aralkyl, halo, haloalkyl, cyano, OR₅, CO₂R₅, CONR₅R₆, etc.; R₃ = (substituted) heterocyclyl, aryl; R₄ = H, alkyl, halo, haloalkyl, cyano, NO₂, OR₅, CO₂R₅, NR₅R₆, etc.; R₅, R₆ = H, alkyl, aryl, aralkyl; R₈ = alkylene, alkenylene, alkynylene, were prep'd. Thus, N-(4-chlorophenyl)-2-[(4-chloromethyl)-3-chlorothiophen-2-ylcarbonyl]amino]-3-methoxy-5-chlorobenzamide in DMF at 0.degree. was treated with N-methylpiperazine followed by stirring to room temp. to give N-(4-chlorophenyl)-2-[(4-methylpiperazin-1-yl)methyl]-3-chlorothiophen-2-yl]carbonyl]amino]-3-methoxy-5-chlorobenzamide. Title compds. routinely inhibited Factor Xa with Ki<3 nM. An aerosol formulation is given.

IT 229335-90-4P 229336-11-2P 229336-27-0P
 229336-52-1P 229336-53-2P 229336-65-6P
 229336-95-2P 229337-09-1P 229337-12-6P
 229337-14-8P 229337-54-6P 229337-66-0P
 229337-74-0P 229338-02-7P 229340-58-3P
 229340-71-0P 229340-88-9P 229341-14-4P
 229341-37-1P 229341-88-2P 229342-40-9P
 229342-41-0P 229342-43-2P 229483-62-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prep. of heteroarylcarbonylaminobenzamides and related compds. as anticoagulants)

RN 229335-90-4 CAPLUS


CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-4-[(4,5-dihydro-5-methyl-2-oxazolyl)methylamino]methyl] - (9CI) (CA INDEX NAME)



09857751


RN 229336-11-2 CAPLUS

CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-4-[(methyl[3-(methylthio)methyl]-1,2,4-oxadiazol-5-yl)methyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 229336-27-0 CAPLUS

CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-4-[(4-ethyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)



RN 229336-52-1 CAPLUS

CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-4-[(2-(ethylimino)-5,5-dimethyl-3-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 229336-53-2 CAPLUS

CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-4-[(5S)-2-imino-5-methyl-3-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

09857751




RN 229336-65-6 CAPLUS

CN 2-Thiophenecarboxamide, 4-[(2-amino-4,5-dihydro-4-oxo-1H-imidazol-1-yl)methyl]-3-chloro-N-[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 229336-95-2 CAPLUS


CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-4-[(2-(1-methylethyl)-1H-imidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 229337-09-1 CAPLUS


CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-4-[(4,5-dihydro-1H-imidazol-2-yl)thiomethyl]- (9CI) (CA INDEX NAME)

09857751




RN 229337-12-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-4-(4,5-dihydro-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 229337-14-8 CAPLUS


CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-4-[(1-iminoethyl)methylamino]methyl- (9CI) (CA INDEX NAME)



RN 229337-54-6 CAPLUS


CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-(4-morpholinyl)phenyl]-4-[(4,5-dihydro-2-oxazolyl)ethylamino]methyl- (9CI) (CA INDEX NAME)

09857751




RN 229337-66-0 CAPLUS

CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-[2-(2-methoxyethoxy)ethoxy]phenyl]-4-[(4,5-dihydro-2-oxazolyl)methylamino]methyl]- (9CI) (CA INDEX NAME)



RN 229337-74-0 CAPLUS

CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4-[(methyl(methylsulfonyl)amino)methyl]- (9CI) (CA INDEX NAME)



RN 229338-02-7 CAPLUS


CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-4-[(2,6-diamino-7H-purin-7-yl)amino]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 229338-01-6


CMF C24 H19 Cl3 N10 O3 S

09857751



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 229340-58-3 CAPLUS
CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-4-[(5-hydroxymethyl)-1-methyl-1H-imidazol-2-yl]thio]methyl-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 229337-10-4
CMF C24 H20 Cl13 N5 O4 S2



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 229340-71-0 CAPLUS
CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-4-[(4,5-dihydro-2-oxazolyl)thio]methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

09857751


CM 1

CRN 229340-70-9
CMF C22 H17 Cl3 N4 O4 S2




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 229340-88-9 CAPLUS

CN 2-Thiophenecarboxamide, 3-chloro-N-[(4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl)-4-[(cyanomethyl)methylamino]methyl]- (9CI) (CA INDEX NAME)




RN 229341-14-4 CAPLUS

CN 2-Thiophenecarboxamide, 4-[(6-amino-7H-purin-7-yl)methyl]-3-chloro-N-[(4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 229336-87-2
CMF C24 H17 Cl3 N8 O3 S

09857751



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 229341-37-1 CAPLUS
CN 2-Thiophenecarboxamide, 4-[[[(aminocarbonyl)methylamino]methyl]-3-chloro-N-[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 229335-56-2
CMF C21 H18 C13 N5 O4 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 229341-88-2 CAPLUS
CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4-[[methyl(methylsulfonyl)amino]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 229337-74-0
CMF C26 H28 C13 N5 O5 S2

09857751



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 229342-40-9 CAPLUS
CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-4-[[2-(cyanomethyl)-4,5-dihydro-1H-imidazol-1-yl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 229336-48-5
CMF C24 H19 Cl3 N6 O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



09857751


RN 229342-41-0 CAPLUS

CN 2-Thiophenecarboxamide, 3-chloro-N-[(4-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-4-[(4,5-dihydro-2-(2-hydroxyethyl)amino)-1H-imidazol-1-yl]methyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 229336-72-5


CMF C24 H23 Cl3 N6 O4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 229342-43-2 CAPLUS

CN 2-Thiophenecarboxamide, 3-chloro-N-[(4-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-4-[(2-(hydroxymethyl)-1H-imidazol-1-yl)methyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 229336-41-8


CMF C23 H18 Cl3 N5 O4 S



CM 2

09857751


CRN 76-05-1
CMF C2 H F3 O2



RN 229483-62-9 CAPLUS
CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[(5-chloro-2-pyridinyl)amino]carbonyl]-6-methoxyphenyl]-4-[[4(or 5)-(hydroxymethyl)-1H-imidazol-1-yl]methyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 229483-61-8
CMF C23 H18 Cl3 N5 O4 S
CCI IDS



D1-CH₂-OH

CM 2

CRN 76-05-1
CMF C2 H F3 O2



09857751

=> d his

(FILE 'HOME' ENTERED AT 12:05:36 ON 09 DEC 2002)

FILE 'REGISTRY' ENTERED AT 12:05:43 ON 09 DEC 2002

L1 STRUCTURE uploaded
L2 50 S L1
L3 STRUCTURE uploaded
L4 50 S L3

FILE 'STNGUIDE' ENTERED AT 12:12:01 ON 09 DEC 2002

FILE 'REGISTRY' ENTERED AT 12:15:50 ON 09 DEC 2002

L5 STRUCTURE uploaded
L6 13 S L5
L7 STRUCTURE uploaded
L8 12 S L7
L9 200 S L7 SSS FULL

FILE 'CAPLUS' ENTERED AT 12:18:32 ON 09 DEC 2002

L10 53 S L9
L11 33 S L10 AND PATENT/DT
L12 1 S L11 AND XA
L13 1 S L10 AND ANTITHROMBOTIC

FILE 'STNGUIDE' ENTERED AT 12:21:30 ON 09 DEC 2002

FILE 'REGISTRY' ENTERED AT 12:33:53 ON 09 DEC 2002

L14 STRUCTURE uploaded
L15 1 S L14 SUB=L9 SAMPLE
L16 8 S L14 SSS FULL SUB=L9

FILE 'CAPLUS' ENTERED AT 12:36:19 ON 09 DEC 2002

L17 2 S L16

FILE 'STNGUIDE' ENTERED AT 12:38:46 ON 09 DEC 2002

FILE 'REGISTRY' ENTERED AT 12:42:14 ON 09 DEC 2002

L18 STRUCTURE uploaded
L19 1 S L18 SUB=L9 SAMPLE
L20 STRUCTURE uploaded
L21 50 S L20
L22 1 S L20 SUB=L9 SAMPLE
L23 STRUCTURE uploaded
L24 1 S L23 SAMPLE SUB=L9
L25 25 S L23 FULL SUB=L9

FILE 'CAPLUS' ENTERED AT 12:50:15 ON 09 DEC 2002

L26 7 S L25
L27 5 S L26 NOT L17
 E BEIGHT D/IN
L28 40 S E4-E5
L29 1 S L10 AND L28
L30 0 S L29 NOT L26
L31 2 S L26 NOT L27

FILE 'REGISTRY' ENTERED AT 13:02:07 ON 09 DEC 2002

L32 STRUCTURE uploaded
L33 50 S L32
L34 0 S L33 SUB=L9 SAMPLE

FILE 'CAPLUS' ENTERED AT 13:03:52 ON 09 DEC 2002

L35 5 S L33

=> s 110 not 135
L36 52 L10 NOT L35

=> s 110 not 126
L37 46 L10 NOT L26


=> s 137 and x
 1272907 X
L38 11 L37 AND X

=> s 138 and factor
 748019 FACTOR
L39 1 L38 AND FACTOR


09857751

L39 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS
AN 2002:487387 CAPLUS
DN 137:63257
TI Preparation of benzamides as inhibitors of production and release of inflammatory cytokines
IN Muto, Susumu; Nagano, Tatsuo; Saotome, Tomomi; Itai, Akiko
PA Institute of Medicinal Molecular Design Inc., Japan
SO PCT Int. Appl., 313 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002049632	A1	20020627	WO 2001-JP11084	20011218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002022683	A5	20020701	AU 2002-22683	20011218
PRAI JP 2000-383202	A	20001218		
WO 2001-JP11084	W	20011218		
OS MARPAT 137:63257				
GI				



AB The title compds. I (wherein X is a connecting group; A is hydrogen or acetyl; E is aryl or heteroaryl; and Z is arene or heteroarene) are prep'd. In an *in vitro* test using cells, 5-chloro-2-hydroxy-N-(4-methoxynaphthalen-2-yl)benzamide at 1 μ g/mL gave 95.1% inhibition of NF- κ B activation.
IT 439144-13-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of benzamides as inhibitors of prodn. and release of inflammatory cytokines)
RN 439144-13-5 CAPLUS
CN Benzamide, 5-chloro-N-(4-chloro-6-methoxy-2-pyrimidinyl)-2-hydroxy- (9CI)
(CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT